Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Haematological Diseases Using a Reduced Intensity Conditioning Regimen
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying the side effects of donor umbilical cord blood transplant after cyclophosphamide, fludarabine phosphate, and total-body irradiation in treating patients with hematologic disease.
研究概览
地位
条件
详细说明
OBJECTIVES:
- To assess the safety and efficacy of unrelated-donor umbilical cord blood transplantation (UCBT) using a nonmyeloablative preparative regimen in patients with hematological disease, in a multi-institution UK setting.
- To confirm that unrelated-donor UCBT following nonmyeloablative conditioning is associated with consistent and durable engraftment in these patients.
- To assess transplant-related mortality at day 100 associated with nonmyeloablative UCBT in these patients.
- To assess the incidence of grades II-IV and III-IV acute graft-vs-host disease (GVHD) in these patients.
- To assess the risk of relapse and progressive disease in these patients at 1 year post transplant after nonmyeloablative UCBT.
- To assess overall and progression-free survival of these patients at 1 year after nonmyeloablative UCBT.
- To assess immune reconstitution at 1, 2, 3, 6, 12, and 24 months after transplant as measured by quantitative recovery of B, T, and NK cells (flow cytometry), qualitative recovery of T cells (TREC and spectratyping), in vivo functional T-cell responses (EBV and CMV tetramers), and quantitative immunoglobulins.
OUTLINE: This is a multicenter study.
- Reduced-intensity conditioning regimen: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -2. Patients undergo a single fraction of total-body irradiation on day -1.
- Umbilical cord blood (UCB) transplantation: Patients undergo umbilical cord blood transplantation on day 0.
- Graft-vs-host disease prophylaxis: Patients receive cyclosporine IV or orally on days -3 to 100 followed by taper and mycophenolate mofetil IV or orally on days -3 to 35 followed by taper.
Blood and bone marrow samples are collected periodically for analysis.
After completion of study treatment, patients are followed up every 3 months in year 1, every 4 months in year 2, every 6 months until 5 years, and then annually thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
England
-
Bristol、England、英国、BS2 8BJ
- 招聘中
- Bristol Royal Hospital for Children
-
接触：
- Contact Person
- 电话号码：44-117-342-8044
-
Leeds、England、英国、LS16 6QB
- 招聘中
- Cancer Research UK Clinical Centre at St. James's University Hospital
-
接触：
- Contact Person
- 电话号码：44-113-206-6020
-
London、England、英国、WC1N 3JH
- 招聘中
- Great Ormond Street Hospital for Children
-
接触：
- Contact Person
- 电话号码：44-207-813-8335
-
London、England、英国、WC1E 6DD
- 招聘中
- UCL Cancer Institute
-
接触：
- Contact Person
- 电话号码：44-207-830-2301
-
London、England、英国、NW1 2PQ
- 招聘中
- University College of London Hospitals
-
接触：
- Rachael Hough, MD
- 电话号码：44-845-155-5000 ext. 5239
-
Newcastle-Upon-Tyne、England、英国、NE2 4HH
- 招聘中
- University of Newcastle-Upon-Tyne Northern Institute for Cancer Research
-
接触：
- Contact Person
- 电话号码：44-191-222-7785
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
Diagnosis of high-risk, advanced or poorly responding hematological disease for which a reduced-intensity hemopoietic stem cell transplantation is likely to be effective
- Disease status is such that there is no alternative therapy likely to achieve a cure or provide a significant prolongation of disease-free survival
- No chronic myelogenous leukemia in first chronic phase responding to imatinib or refractory blast crisis
- No acute leukemia in morphological relapse/persistent disease (defined as > 5% blasts in normocellular bone marrow)
- No malignant disease that is refractory to or progressive on salvage therapy
- No myelofibrosis
Donor must be matched at HLA-A and -B at antigen level and HLA-DRB1 at allelic level
- No available 5-6/6 HLA-A, -B, -DRB1 matched sibling donor OR 10/10 unrelated volunteer donor
PATIENT CHARACTERISTICS:
- Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100% (pediatrics)
- Transaminases < 5 times upper limit of normal (ULN)
- Bilirubin < 3 times ULN
- Creatinine clearance > 50 mL/min
- DLCO > 50% predicted
- No supplemental oxygen requirements
- Not pregnant or nursing
- Negative pregnancy test
- No HIV or HTLV (I and II) antibody positivity or evidence of infection
- No acquired aplastic anemia
- No decompensated congestive heart failure or uncontrolled arrhythmia and left ventricular ejection fraction ≥ 35%
- No current active serious infection, in particular uncontrolled fungal infection
- No congenital immune deficiencies
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 6 months since prior exposure to combination chemotherapy OR only 1 course of induction combination chemotherapy for myelodysplastic syndromes or acute myeloid leukemia (please discuss with study coordinator/s if this course contained fludarabine)
- At least 6 months since prior myeloablative bone marrow transplantation
- No prior irradiation that precludes the safe administration of an additional dose of 200 cGy of total-body irradiation
- No prior autograft
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：非随机化
- 屏蔽：无（打开标签）
研究衡量的是什么？
主要结果指标
结果测量 |
|---|
|
Non-relapse mortality at day 100
|
次要结果测量
结果测量 |
|---|
|
Incidence of grades II-IV and III-IV acute graft-vs-host disease (GVHD) at day 100 and chronic GVHD at 1 year
|
|
Mixed chimerism
|
|
Hemopoietic recovery
|
合作者和调查者
调查人员
- 首席研究员：Rachael Hough, MD、University College London Hospitals
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.